All In Biotech

Drug Trial Radar · NCT03260023

Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers

A Phase Ib/II Trial Evaluating the Combination of TG4001 and Avelumab in Patients With HPV-16 Positive Recurrent or Metastatic Malignancies.

Last checked: Nov 19, 2026Latest source record: Feb 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 143 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

143

Actual

Start

Sep 1, 2017

Primary completion

Sep 18, 2024

Study completion Dec 2026

Sponsor

Lead sponsor
TransgeneIndustry
Sponsor type
Industry
Collaborators
Merck KGaA, Darmstadt, Germany; EMD Serono Research & Development Institute, Inc.; Pfizer
First posted
Aug 24, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will consist of two parts : In the phase Ib: safety will be assessed in consecutive cohorts of 3 to 6 participants at increasing doses of TG4001 in combination with avelumab according to a 3+3 design. There will be no intra-participant dose escalation. In the phase II part 1, evaluation of efficacy and further evaluation of safety of the combination of TG4001 and avelumab will be performed in a single arm of participants with recurrent or metastatic HPV-16 positive advanced malignancies. In the phase II part 2, evaluation of efficacy of the combination of TG4001 and avelumab will be performed in a randomized, open-label controlled study comparing TG4001 in combination with avelumab to avelumab alone in participants with HPV-16 positive advanced malignancies. In both phases, evaluation of tumor response will be done locally according to RECIST 1.1. All participants will be followed up until disease progression, death, or unacceptable toxicity, or study withdrawal for any reason, whichever occurs first.

Conditions

  • HPV-Related Carcinoma
  • HPV-Related Cervical Carcinoma
  • HPV-Related Anal Squamous Cell Carcinoma
  • HPV-Related Penile Squamous Cell Carcinoma
  • HPV-Related Vulvar Squamous Cell Carcinoma

Interventions

  • TG4001Biological

    PhIb: Dose escalation PhII: Established RP2D for TG4001

  • AvelumabDrug

    Anti PD-L1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ib: To Evaluate the Safety and Tolerability of the Combination of TG4001 Plus Avelumab in Participants With Recurrent or Metastatic HPV-16 Positive Advanced MalignanciesTime frame: From Day 1 to Day 28
  2. Phase II Part 1: Overall Response Rate (ORR) by RECIST 1.1Time frame: From treatment start, every 6 weeks for the first 9 months, then every 12 weeks up to 2 years.
  3. Phase II Part 2 Cohort A: Progression Free Survival (PFS) by RECIST 1.1Time frame: From randomization: Every 6 weeks for the first 9 months, then every 12 weeks through study completion, for an average of 1 year.
  4. Progression Free Survival (PFS) Phase II Part 2 Cohort A by StratificationTime frame: From randomization: Every 6 weeks for the first 9 months, then every 12 weeks through study completion, for an average of 1 year.

Locations

20 sites in 3 countries. Site status is shown where the registry gives one.

  • Mayo Clinic

    Jacksonville, Florida

  • Mayo Clinic

    Rochester, Minnesota

  • I.C.O. Paul Papin

    Angers, France

  • CHU Besançon

    Besançon, France

  • Hôpital Saint André - CHU de Bordeaux

    Bordeaux, France

  • Hôpitaux Civils de Colmar - Hôpital Pasteur

    Colmar, France

  • CLCC Georges-François Leclerc

    Dijon, France

  • Centre Léon Bérard

    Lyon, France

  • Hopital de la Timone

    Marseille, France

  • Institut Curie

    Paris, France

  • I.C.O. Gauducheau

    Saint-Herblain, France

  • Centre Paul Strauss - ICANS - Institut de cancérologie Strasbourg Europe

    Strasbourg, France

  • Institut Claudius Regaud - IUCT - Oncopole

    Toulouse, France

  • Institut Gustave Roussy

    Villejuif, France

  • ICO Badalona - Hospital Germans Trias i Pujol

    Badalona, Spain

  • Hospital Virgen de las Nieves

    Granada, Spain

  • Fundación de Investigación biomédica H. 12 de Octubre

    Madrid, Spain

  • Fundación de Investigación Biomédica Hospital Clínico San Carlos

    Madrid, Spain

  • Hospital Virgen de La Victoria

    Málaga, Spain

  • Hospital General de Valencia

    Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.